RU2218178C2 - Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение - Google Patents
Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение Download PDFInfo
- Publication number
- RU2218178C2 RU2218178C2 RU2000114841/14A RU2000114841A RU2218178C2 RU 2218178 C2 RU2218178 C2 RU 2218178C2 RU 2000114841/14 A RU2000114841/14 A RU 2000114841/14A RU 2000114841 A RU2000114841 A RU 2000114841A RU 2218178 C2 RU2218178 C2 RU 2218178C2
- Authority
- RU
- Russia
- Prior art keywords
- vasp
- use according
- phosphoserine
- phosphoprotein
- biological material
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract 4
- 108010089430 Phosphoproteins Proteins 0.000 title abstract 2
- 102000007982 Phosphoproteins Human genes 0.000 title abstract 2
- 239000003071 vasodilator agent Substances 0.000 title abstract 2
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 claims abstract 10
- 239000012634 fragment Substances 0.000 claims abstract 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims abstract 2
- 239000000032 diagnostic agent Substances 0.000 claims abstract 2
- 229940039227 diagnostic agent Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 230000008694 endothelial dysfunction Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 102000049398 Vasodilator-stimulated phosphoproteins Human genes 0.000 claims 7
- 239000012620 biological material Substances 0.000 claims 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000006916 protein interaction Effects 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Computational Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Изобретение относится к медицине и касается моноклональных антител против VASP (стимулированного вазодилататором фосфопротеина), которые связывают VASP как антиген только тогда, когда VASP присутствует в фосфорилированной форме, к гибридомным клеткам для их получения и к применению антител или фрагментов антител в качестве диагностических средств и/или лечебных средств. Преимущество изобретения заключается в разработке новых подходов идентификации эндотелиальной дисфункции. 5 с. и 7 з.п. ф-лы, 1 табл.
Description
Текст описания в факсимильном виде (см. графическую часть).
Claims (14)
1. Моноклональное антитело 16С2, которое продуцируется гибридомной клеточной линией, имеющей регистрационный номер DSM ACC 2330, или его фрагменты, способные связывать стимулированный вазодилататором фосфопротеин (VASP) только тогда, когда VASP фосфорилирован по положению серина-239 (фосфосерин-239 VASP).
2. Применение антитела 16С2 или его фрагментов, как определено в п.1, в качестве диагностического агента.
3. Применение по п.2 для качественного или количественного определения фосфосерина-239 VASP в биологическом материале.
4. Применение по п.3, где биологическим материалом являются тромбоциты человека или кровь человека.
5. Применение по п.3 или 4, где определение фосфосерина-239 осуществляют методом Вестерн-блоттинга.
6. Применение по п.3 или 4, где определение фосфосерина-239 осуществляют с помощью проточной цитометрии.
7. Применение по любому из пп.2-6 для обнаружения веществ, которые влияют на уровень cGMP и/или сАМР в биологическом материале.
8. Применение по любому из пп.2-6 для определения активности эндотелиальных факторов in vivo.
9. Применение по любому из пп.2-8 для обнаружения дисфункции эндотелия.
10. Гибридомная линия клеток DSM ACC 2330, которая продуцирует моноклональное антитело 16С2.
11. Диагностический набор, содержащий антитело 16С2 или его фрагмент, как определено в п.1.
12. Диагностический способ, который включает в себя применение антитела 16С2 или его фрагментов, как определено в п.1, для определения или влияния статуса фосфорилирования фосфосерина-239 VASP и/или белковых взаимодействий VASP в биологическом материале.
Приоритет по пунктам:
07.11.1997 по пп.1-12;
26.03.1998 - по внесенным изменениям в пункты формулы.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19749091A DE19749091C1 (de) | 1997-11-07 | 1997-11-07 | Antikörper gegen phosphoryliertes VASP (Vasodilator-Stimuliertes Phosphoprotein), Hybridomzellen zu dessen Herstellung sowie dessen Anwendung |
| DE19749091.3 | 1997-11-07 | ||
| US7937598P | 1998-03-26 | 1998-03-26 | |
| US60/079,375 | 1998-03-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000114841A RU2000114841A (ru) | 2002-06-20 |
| RU2218178C2 true RU2218178C2 (ru) | 2003-12-10 |
Family
ID=26041380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000114841/14A RU2218178C2 (ru) | 1997-11-07 | 1998-11-06 | Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6649421B1 (ru) |
| EP (1) | EP1042368B1 (ru) |
| JP (1) | JP5031140B2 (ru) |
| KR (1) | KR100513418B1 (ru) |
| CN (1) | CN1188426C (ru) |
| AT (1) | ATE248189T1 (ru) |
| AU (1) | AU753557B2 (ru) |
| BR (1) | BR9813988A (ru) |
| CA (1) | CA2308604C (ru) |
| CZ (1) | CZ299889B6 (ru) |
| ES (1) | ES2205593T3 (ru) |
| HU (1) | HU222411B1 (ru) |
| PL (1) | PL195985B1 (ru) |
| RU (1) | RU2218178C2 (ru) |
| TR (1) | TR200001265T2 (ru) |
| WO (1) | WO1999024473A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10029210A1 (de) * | 2000-06-14 | 2002-01-31 | Vasopharm Biotech Gmbh & Co Kg | Testsystem sowie dessen Verwendung |
| US6951947B2 (en) * | 2000-07-13 | 2005-10-04 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| EP1182263A1 (en) * | 2000-08-11 | 2002-02-27 | Evotec OAI AG | Process for detecting threonine/serine kinase activity |
| US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
| AU2002221132A1 (en) * | 2000-12-13 | 2002-07-01 | Taisho Pharmaceutical Co. Ltd. | Novel antibody |
| CA2445420A1 (en) | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
| US7619059B2 (en) | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
| WO2005088308A2 (en) * | 2004-03-12 | 2005-09-22 | The Scripps Research Institute | Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities |
| CN103102411A (zh) * | 2009-06-11 | 2013-05-15 | 北京华大蛋白质研发中心有限公司 | 一种制备针对糖基化修饰蛋白质的单克隆抗体杂交瘤的方法 |
| FR2946756A1 (fr) * | 2009-06-12 | 2010-12-17 | Biocytex | Dosage en sang total d'un biomarqueur intracellulaire appartenant a une voie de signalisation cellulaire- utilisation pour mesurer l'activation d'une population cellulaire determinee |
| EP3509613A4 (en) * | 2016-09-07 | 2020-12-02 | Vanderbilt University | VASOACTIVE POLYPEPTIDE FOR THE RELAXATION OF SMOOTH MUSCLES |
| CN112730826A (zh) * | 2020-12-23 | 2021-04-30 | 中南大学湘雅三医院 | 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 |
| CN113238062B (zh) * | 2021-07-13 | 2021-09-28 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激磷蛋白光激化学发光均相免疫检测试剂盒及其检测方法 |
| CN114002440B (zh) * | 2021-12-30 | 2022-04-01 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激蛋白的酶联免疫检测试剂盒及其检测方法 |
| CN120248113B (zh) * | 2025-06-05 | 2025-12-02 | 北京赛斯维德生物科技有限公司 | 一种磷酸化VASP-Ser 239蛋白抗体及其应用 |
| CN120254291B (zh) * | 2025-06-05 | 2025-10-17 | 中国质量检验检测科学研究院 | 一种检测非洲猪瘟病毒中和抗体的便携式免疫层析装置及其应用 |
| CN120271704B (zh) * | 2025-06-05 | 2025-11-11 | 北京赛斯维德生物科技有限公司 | 一种识别vasp的抗体及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334053T2 (de) | 1992-04-10 | 2007-01-04 | Dana-Farber Cancer Institute, Inc., Boston | Immunnachweis eines aktivierungszustandsspezifischen phosphoproteins |
-
1998
- 1998-11-06 PL PL98340465A patent/PL195985B1/pl not_active IP Right Cessation
- 1998-11-06 CN CNB988114542A patent/CN1188426C/zh not_active Expired - Fee Related
- 1998-11-06 AT AT98963419T patent/ATE248189T1/de not_active IP Right Cessation
- 1998-11-06 KR KR10-2000-7004901A patent/KR100513418B1/ko not_active Expired - Fee Related
- 1998-11-06 CZ CZ20001684A patent/CZ299889B6/cs not_active IP Right Cessation
- 1998-11-06 EP EP98963419A patent/EP1042368B1/en not_active Expired - Lifetime
- 1998-11-06 CA CA002308604A patent/CA2308604C/en not_active Expired - Fee Related
- 1998-11-06 BR BR9813988-6A patent/BR9813988A/pt not_active IP Right Cessation
- 1998-11-06 RU RU2000114841/14A patent/RU2218178C2/ru not_active IP Right Cessation
- 1998-11-06 HU HU0004099A patent/HU222411B1/hu not_active IP Right Cessation
- 1998-11-06 ES ES98963419T patent/ES2205593T3/es not_active Expired - Lifetime
- 1998-11-06 TR TR2000/01265T patent/TR200001265T2/xx unknown
- 1998-11-06 JP JP2000520481A patent/JP5031140B2/ja not_active Expired - Fee Related
- 1998-11-06 WO PCT/EP1998/007103 patent/WO1999024473A1/en not_active Ceased
- 1998-11-06 US US09/530,864 patent/US6649421B1/en not_active Expired - Fee Related
- 1998-11-06 AU AU18712/99A patent/AU753557B2/en not_active Ceased
-
2003
- 2003-09-22 US US10/664,970 patent/US20040063914A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Blick, 1/97, Wiirzburg University, pp. 79-81. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ299889B6 (cs) | 2008-12-29 |
| US20040063914A1 (en) | 2004-04-01 |
| CA2308604A1 (en) | 1999-05-20 |
| WO1999024473A1 (en) | 1999-05-20 |
| CN1279691A (zh) | 2001-01-10 |
| TR200001265T2 (tr) | 2000-09-21 |
| US6649421B1 (en) | 2003-11-18 |
| KR20010031830A (ko) | 2001-04-16 |
| CA2308604C (en) | 2009-12-15 |
| AU1871299A (en) | 1999-05-31 |
| ATE248189T1 (de) | 2003-09-15 |
| JP5031140B2 (ja) | 2012-09-19 |
| JP2001522865A (ja) | 2001-11-20 |
| HUP0004099A3 (en) | 2002-01-28 |
| AU753557B2 (en) | 2002-10-24 |
| PL340465A1 (en) | 2001-02-12 |
| EP1042368B1 (en) | 2003-08-27 |
| EP1042368A1 (en) | 2000-10-11 |
| KR100513418B1 (ko) | 2005-09-09 |
| CN1188426C (zh) | 2005-02-09 |
| HU222411B1 (hu) | 2003-06-28 |
| CZ20001684A3 (cs) | 2000-11-15 |
| PL195985B1 (pl) | 2007-11-30 |
| BR9813988A (pt) | 2000-09-26 |
| ES2205593T3 (es) | 2004-05-01 |
| HUP0004099A1 (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2218178C2 (ru) | Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение | |
| Battifora et al. | A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms | |
| Lanier et al. | Paraformaldehyde fixation of hematopoietic cells for quantitative flow cytometry (FACS) analysis | |
| Dalchau et al. | Identification and unusual tissue distribution of the canine and human homologues of Thy-1 (theta). | |
| Lindqvist et al. | Human antibodies to vascular endothelium | |
| BR9809443A (pt) | Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão. | |
| RU2000114841A (ru) | Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение | |
| Bjerke et al. | Identification of mononuclear cells in situ in skin lesions of lichen planus | |
| Konttinen et al. | Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis. | |
| JPS63127161A (ja) | 化学阻止剤およびこれを使用するイムノアッセイ法並びにイムノアッセイ用キット | |
| Collings et al. | The demonstration of cell surface antigens on T cells, B cells and accessory cells in paraffin-embedded human tissues | |
| HUNDER et al. | Complement in pericardial fluid of lupus erythematosus: studies in two patients | |
| Swart et al. | An immunodiffusion method for the identification of the species of origin of meat samples | |
| Moll et al. | Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas | |
| ES8501630A1 (es) | Un metodo para detectar o vigilar el estado de una condicion patologica humana que implica proteina de tejido conjuntivo. | |
| Okamura et al. | Single-cell immunofluorescence assay for terminal transferase: human leukaemic and non-leukaemic cells | |
| EP0387027A3 (en) | Endometriosis diagnosis methods and reagents | |
| ATE427494T1 (de) | Verfahren zur quantifizierung der akt-protein- expression | |
| Fritsch et al. | XC Protein Components of Human Perilymph: I. Preliminary Study | |
| Nyland et al. | Localization of Fcy receptors in the human central nervous system | |
| Lindström | Kappa: lambda light chain ratio in IgG eluted from rheumatoid arthritis synovium | |
| DE59300909D1 (de) | Verfahren zur immunologischen erkennung maligner tumore und kit zur durchführung dieses verfahrens. | |
| Thoenes | The immunohistology of glomerulonephritis—distinctive marks and variability | |
| Riggio et al. | Alpha-2-hyperglobulinaemia as a humoral indicator of the homograft reaction | |
| Oehmichen | Characterization of mononuclear phagocytes in human CSF using membrane markers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20101107 |